Cullinan Oncology
CGEM
103 hedge funds and large institutions have $330M invested in Cullinan Oncology in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 11 closing their positions.
93% more call options, than puts
Call options by funds: $29K | Put options by funds: $15K
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
7% more funds holding
Funds holding: 96 → 103 (+7)
0.01% more ownership
Funds ownership: 82.03% → 82.04% (+0.01%)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
17% less capital invested
Capital invested by funds: $396M → $330M (-$66.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.17M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.52M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$827K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$625K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$608K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$47.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.69M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.41M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.84M |
| 5 |
BlackRock
New York
|
-$2.76M |
CGEM Hedge Fund Activity: Q1 2023 in Review
103 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2023, worth a combined $330M — down 17% from $396M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CGEM positions and 11 closed out — a net gain of 7 holders — while 30 added to existing stakes and 34 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.17M. The largest seller was BVF Inc, cutting an estimated $47.5M.
- 103 institutional investors held Cullinan Oncology (CGEM) as of Q1 2023, up from 96 in Q4 2022.
- Funds reported $330M of Cullinan Oncology stock for Q1 2023, down 17% quarter-over-quarter.
- 18 funds opened new Cullinan Oncology positions in Q1 2023 and 11 closed out, a net change of +7 holders.
- The largest Cullinan Oncology buyer in Q1 2023 was Citadel Advisors, an estimated $4.17M added.
- The largest Cullinan Oncology seller in Q1 2023 was BVF Inc, an estimated $47.5M sold.
Based on aggregated 13F filings for Q1 2023.